A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.

Trial Profile

A multi-centre, double-blind, randomised-withdrawal, parallel-group, placebo-controlled phase III study of the efficacy and safety of quetiapine fumarate sustained release (Seroquel SR (TM)) as monotherapy in the maintenance treatment of patients with major depressive disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2017

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Depression; Major depressive disorder
  • Focus Therapeutic Use
  • Acronyms AMETHYST
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 Jul 2012 Results published in the International Clinical Psychopharmacology.
    • 16 Sep 2009 Results of a secondary analysis investigating the effects of quetiapine on functioning and sleep quality have been presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology.
    • 03 May 2008 Results have been presented at the 161st Annual Meeting of the American Psychiatric Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top